Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs ARESTOCAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Hydrolyzed by plasma esterases.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Minimal; <5% bound to plasma proteins.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
No dose adjustment required; negligible systemic absorption.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No dose adjustment required; negligible systemic absorption.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
There is no FDA black box warning for Arestocaine hydrochloride.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to any component of the formulation.
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
None known.
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs ARESTOCAINE HYDROCHLORIDE, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and ARESTOCAINE HYDROCHLORIDE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and ARESTOCAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.